

STATEMENT OF APPROVED BUDGET, UTILIZATION, DISBURSEMENTS AND BALANCES FOR TRUST RECEIPTS
 (for Implementing Agency use only)
 As of the Quarter Ending December 31, 2021

Department : State Universities and Colleges (SUCs)
 Agency : University of the Philippine System
 Operating Unit : University of the Philippines, Manila
 Organization Code(UACS) :
 Fund Cluster : 07 - Trust Receipts
 Date Exported : January 13, 2022, 01:20:23 PM

Inter Agency Fund Transfer

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (10-19) = (17-18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+(-)4)	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
CHED		2,000,000.00		2,000,000.00		748,429.59	1,219,058.16		1,967,487.75		748,429.59	1,219,058.16		1,967,487.75	31,512.25		
		2,000,000.00		2,000,000.00		748,429.59	1,219,058.16		1,967,487.75		748,429.59	1,219,058.16		1,967,487.75	31,512.25		
UPM Unfolding the Genomic Diversity and Origin of Multi-Drug Resistant Mycobacterium Tuberculosis in the Philippines (140-6)		2,000,000.00		2,000,000.00		748,429.59	1,219,058.16		1,967,487.75		748,429.59	1,219,058.16		1,967,487.75	31,512.25		
PS		761,416.84		761,416.84		728,904.59			728,904.59		728,904.59			728,904.59	31,512.25		
MOOE		1,238,583.16		1,238,583.16		19,525.00	1,219,058.16		1,238,583.16		19,525.00	1,219,058.16		1,238,583.16			
Dangerous Drugs Board		4,000,000.00		4,000,000.00		180,508.80	270,913.20		451,422.00		180,508.80	270,913.20		451,422.00	3,548,578.00		
		4,000,000.00		4,000,000.00		180,508.80	270,913.20		451,422.00		180,508.80	270,913.20		451,422.00	3,548,578.00		
UPM Development and Validation of a Plastic-Based Microfluidic POCT-Device (E-test) Used to Detect Infection With Selected New Psychoactive Substances and Pharmaceuticals (104)		4,000,000.00		4,000,000.00		180,508.80	270,913.20		451,422.00		180,508.80	270,913.20		451,422.00	3,548,578.00		
PS		2,052,979.20		2,052,979.20		180,508.80	270,763.20		451,272.00		180,508.80	270,763.20		451,272.00	1,601,707.20		
MOOE		1,787,020.80		1,787,020.80			150.00		150.00			150.00		150.00	1,786,870.80		
CO		160,000.00		160,000.00											160,000.00		
UPM AHPD & SRA and Life Insurance, Meals & Accommodation of Healthworkers in Response to COVID-19 Health Emergency (103-38D)		1,421,060.00		1,421,060.00		1,012,469.09			1,012,469.09		1,012,469.09			1,012,469.09	408,590.91		
MOOE		1,421,060.00		1,421,060.00		1,012,469.09			1,012,469.09		1,012,469.09			1,012,469.09	408,590.91		
UPM Development and Implementation of Biosafety and Molecular Biology Training Courses for Lab. Personnel Working in COVID-19 Testing Centers (103-24F)		5,308,019.96		5,308,019.96			4,376,752.97		4,376,752.97			4,376,752.97		4,376,752.97	931,266.99		
PS		4,658,300.00		4,658,300.00			4,359,700.00		4,359,700.00			4,359,700.00		4,359,700.00	298,600.00		
MOOE		534,719.96		534,719.96			17,052.97		17,052.97			17,052.97		17,052.97	517,666.99		
CO		115,000.00		115,000.00											115,000.00		
UPM Development of 5 Clinical Practice Guidelines (103-25)		700,000.00		700,000.00		104,026.67			104,026.67		104,026.67			104,026.67	595,973.33		
MOOE		700,000.00		700,000.00		104,026.67			104,026.67		104,026.67			104,026.67	595,973.33		
UPM Development of Medical Certificate on Cause of Death Instructional Design and Advocacy Initiatives to Philippine Medical Schools Curriculum (103-26A)		5,000,000.00	318,382.80	5,318,382.80		1,876,590.00	842,015.20		2,718,605.20		1,876,590.00	842,015.20		2,718,605.20	2,599,777.60		
PS		320,080.00	318,382.80	638,462.80		320,080.00	318,382.80		638,462.80		320,080.00	318,382.80		638,462.80			
MOOE		4,679,920.00		4,679,920.00		1,556,510.00	523,632.40		2,080,142.40		1,556,510.00	523,632.40		2,080,142.40	2,599,777.60		
DOH		45,054,252.01	2,745,977.97	47,800,229.98		8,677,609.18	12,735,811.54	296,678.00	21,710,098.72		8,677,609.18	12,735,811.54	296,678.00	21,710,098.72	26,090,131.26		
		45,054,252.01	2,745,977.97	47,800,229.98		8,677,609.18	12,735,811.54	296,678.00	21,710,098.72		8,677,609.18	12,735,811.54	296,678.00	21,710,098.72	26,090,131.26		
UPM Effect of Baseline Dengue Serostatus Among Tetraivalent Dengue Vaccine CYD-DTV (Dengvaxia) Recipients on Subsequent Virologically Confirmed Dengue in the Philippines (103-21)		8,100,000.00		8,100,000.00		990,339.54	3,450,792.00		4,441,131.54		990,339.54	3,450,792.00		4,441,131.54	3,658,868.46		
PS		3,564,532.80		3,564,532.80		311,060.35	927,356.00		1,238,416.35		311,060.35	927,356.00		1,238,416.35	2,326,116.45		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications, Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Capaid Utilizations (10-19) * (17-18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=[3]+[4]	6	7	8	9	10=[6]+[7]+[8]+[9]	11	12	13	14	15=[11]+[12]+[13]+[14]	16=(5-10)	17	18
MOOE		4,535,467.20		4,535,467.20		679,279.19	1,513,436.00		3,202,715.19		679,279.19	1,513,436.00		3,202,715.19	1,332,752.01		
UPM Evidence Review of Health Technologies (103-27)		200,000.00		200,000.00											200,000.00		
MOOE		200,000.00		200,000.00											200,000.00		
UPM Prevalence of Metabolic and Behavioral Risk Factors Causing Lifestyle-Related Diseases in the National Capital Region (103-22)		1,800,000.00		1,800,000.00		97,141.20	89,846.40		186,987.60		97,141.20	89,846.40		186,987.60	1,613,012.40		
PS		1,005,729.40		1,005,729.40		97,141.20	89,846.40		186,987.60		97,141.20	89,846.40		186,987.60	818,741.80		
MOOE		794,270.60		794,270.60											794,270.60		
UPM Procurement of Supplies, Consumables and other COVID-19 Testing Related Needs in Response to COVID-19 (103-28G)		10,000,000.00		10,000,000.00											10,000,000.00		
MOOE		10,000,000.00		10,000,000.00											10,000,000.00		
UPM Salaries of COVID Lab Staff for the period Sept. 1 to Oct. 31, 2021 (103-28E6)		229,168.18		229,168.18											229,168.18		
PS		229,168.18		229,168.18											229,168.18		
UPM Salaries of COVID Laboratory Staff, January to June 2021 (103-28F)		8,658,097.60		8,658,097.60		3,255,405.48	1,495,164.17		4,750,569.65		3,255,405.48	1,495,164.17		4,750,569.65	3,907,527.95		
PS		8,658,097.60		8,658,097.60		3,255,405.48	1,495,164.17		4,750,569.65		3,255,405.48	1,495,164.17		4,750,569.65	3,907,527.95		
UPM Updating the Philippine Guidelines on Periodic Health Examinations: Phase I (103-30)		1,337,906.27	828,103.37	2,366,009.64		987,000.00	803,731.20	296,678.00	2,087,409.20		987,000.00	803,731.20	296,678.00	2,087,409.20	278,600.44		
PS		550,906.27	835.73	551,742.00			219,777.60	296,678.00	516,455.60			219,777.60	296,678.00	516,455.60	35,286.40		
MOOE		987,000.00	827,267.64	1,814,267.64		987,000.00	583,953.60		1,570,953.60		987,000.00	583,953.60		1,570,953.60	243,314.04		
UPM Updating the Philippine Guidelines on Periodic Health Examinations: Phase I (103-30A)		2,100,000.00	1,599,491.80	3,699,491.80		354,637.20	1,677,509.60		2,032,146.80		354,637.20	1,677,509.60		2,032,146.80	1,667,345.00		
PS		406,800.00	1,599,491.80	2,006,291.80		354,637.20	1,651,654.60		2,006,291.80		354,637.20	1,651,654.60		2,006,291.80	1,667,345.00		
MOOE		1,693,200.00		1,693,200.00			25,855.00		25,855.00			25,855.00		25,855.00	1,667,345.00		
Special Risk Allowance of COVID Lab Staff for May & June 2021 (103-28H1)		1,999,143.60		1,999,143.60											1,999,143.60		
PS		1,999,143.60		1,999,143.60											1,999,143.60		
UPM Project 2: Developing Immersiv - Gamification Technology System for Rehabilitation Management of Pediatric Patients with Cerebral Palsy and Mobility Limitations (Phase I) (107-146)		6,736,770.30		6,736,770.30		869,677.07	419,975.40	935,222.78	2,224,875.25		869,677.07	419,975.40	935,222.78	2,224,875.25	4,511,895.05		
PS		3,828,714.00		3,828,714.00		796,922.27	419,975.40	935,222.78	2,152,120.45		796,922.27	419,975.40	935,222.78	2,152,120.45	1,678,593.55		
MOOE		1,662,892.30		1,662,892.30		72,754.80			72,754.80					72,754.80	1,590,137.50		
CO		1,245,164.00		1,245,164.00											1,245,164.00		
UPM A Molecular Epidemiologic Analysis of Drug-Resistant Mycobacterium Tuberculosis Isolates Derived from the 3rd Philippine TB Drug Resistance Survey 2018 and Community Based Study (107-150)		3,028,019.80		3,028,019.80		150.00	334,733.20	377,054.40	711,937.60		150.00	334,733.20	377,054.40	711,937.60	2,316,082.20		
PS		1,374,384.00		1,374,384.00			334,733.20	377,054.40	711,937.60			334,733.20	377,054.40	711,937.60	662,596.40		
MOOE		1,573,635.80		1,573,635.80		150.00			150.00		150.00			150.00	1,573,485.80		
CO		80,000.00		80,000.00											80,000.00		
UPM All Case Rates Policy: Assessment and Evaluation of Policy Goals (107-153)		1,463,898.40	815,560.00	2,279,458.40		150.00	772,760.00	619,771.70	1,392,681.70		150.00	772,760.00	619,771.70	1,392,681.70	886,776.70		
PS		1,138,898.40	815,560.00	1,954,458.40			772,760.00	612,249.20	1,385,009.20			772,760.00	612,249.20	1,385,009.20	569,449.20		
MOOE		325,000.00		325,000.00		150.00		7,522.50	7,522.50		150.00			7,522.50	317,327.50		
UPM Anti-Coronavirus Therapies to Prevent Progression of COVID-19 (ACT), A RANDOMIZED TRIAL (107-142)		2,979,324.23		2,979,324.23		912,894.63	650,348.15	388,679.20	1,951,921.98		912,894.63	650,348.15	388,679.20	1,951,921.98	1,027,402.25		
PS		2,209,964.40		2,209,964.40		704,884.80	562,532.40	378,877.20	1,646,294.40		704,884.80	562,532.40	378,877.20	1,646,294.40	563,679.00		
MOOE		769,359.83		769,359.83		208,009.83	87,815.75	9,802.00	305,627.58		208,009.83	87,815.75	9,802.00	305,627.58	463,732.25		
UPM Assessment of the Gut Microbiome for COVID-19 Diagnosis and Prognosis (107-131)		4,476,690.00		4,476,690.00		344,050.80	289,746.00	478,016.00	1,111,812.80		344,050.80	289,746.00	478,016.00	1,111,812.80	3,364,877.20		
PS		1,230,384.00		1,230,384.00		344,000.80	289,596.00	245,896.00	882,692.80		344,000.80	289,596.00	245,896.00	882,692.80	347,691.20		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (10-19) + (17-16)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3)+(4)	6	7	8	9	10=(6)+(7)+(8)+(9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
MOOE		1,236,306.00		1,236,306.00		50.00	150.00	228,920.00	229,120.00		50.00	150.00	228,920.00	229,120.00	1,007,186.00		
CD		2,010,000.00		2,010,000.00											2,010,000.00		
UPM Association of Abnormal Coagulation Parameters with Adverse Clinical Outcomes among Patients with Moderate to Severe SARS-CoV-2 Infection Admitted in the University of the Philippines - Philippine General Hospital (UP-PGH) 107-147		1,000,000.00		1,000,000.00			50.00	433,939.46	433,989.46			50.00	433,939.46	433,989.46	566,010.54		
PS		368,262.40		368,262.40				368,262.40	368,262.40				368,262.40	368,262.40			
MOOE		581,737.60		581,737.60			50.00	65,677.06	65,727.06			50.00	65,677.06	65,727.06	516,010.54		
CO		50,000.00		50,000.00											50,000.00		
UPM Association of Abnormal Coagulation Parameters with Adverse Clinical Outcomes among Patients with Moderate to Severe SARS-CoV-2 Infection Admitted in the University of the Philippines - Philippine General Hospital (UP-PGH) 107-147A		3,779,778.40		3,779,778.40				1,667,537.16	1,667,537.16				1,667,537.16	1,667,537.16	2,112,241.24		
PS		1,169,324.80		1,169,324.80				1,133,324.80	1,133,324.80				1,133,324.80	1,133,324.80	36,000.00		
MOOE		2,610,453.60		2,610,453.60				534,212.36	534,212.36				534,212.36	534,212.36	2,076,241.24		
UPM Biochemical and Immunologic Characterization and Cross-reactivity Studies of Allergenic Local Pollen Extracts (107-70)		3,789,392.58		3,789,392.58			802,746.55		802,746.55			802,746.55		802,746.55	2,986,646.03		
PS		491,771.20		491,771.20			431,496.95		431,496.95			431,496.95		431,496.95	60,274.25		
MOOE		2,807,621.38		2,807,621.38			371,249.60		371,249.60			371,249.60		371,249.60	2,436,371.78		
CO		490,000.00		490,000.00											490,000.00		
UPM Development of a Cell-Based In-vitro Assay for Coronavirus Disease 2019 (COVID-19) Serologic Testing (107-140)		4,994,073.84		4,994,073.84		391,452.84	397,291.20		788,744.04		391,452.84	397,291.20		788,744.04	4,205,329.80		
PS		1,182,115.20		1,182,115.20		140,419.20	397,291.20		537,710.40		140,419.20	397,291.20		537,710.40	644,404.80		
MOOE		2,414,958.64		2,414,958.64		251,033.64			251,033.64		251,033.64			251,033.64	2,163,925.00		
CD		1,397,000.00		1,397,000.00											1,397,000.00		
UPM Development of Clinical Practice Guidelines on the Management of Hepatitis B in the Philippines (107-167)		1,049,962.65		1,049,962.65				662,254.80	662,254.80				662,254.80	662,254.80	387,707.85		
PS		419,812.65		419,812.65				32,104.80	32,104.80				32,104.80	32,104.80	387,707.85		
MOOE		630,150.00		630,150.00				630,150.00	630,150.00					630,150.00			
UPM Digital Histologic Image Analysis Software for Hirschsprung's Disease (107-95)		644,966.80		644,966.80		644,966.80			644,966.80		644,966.80			644,966.80			
MOOE		644,966.80		644,966.80		644,966.80			644,966.80		644,966.80			644,966.80			
UPM Durability and Extent of Protection for SARS-CoV-2 Antibodies Among Patients with COVID-19 (107-141)		10,799,884.63		10,799,884.63		1,210,944.80	3,249,857.40	1,779,250.80	6,240,053.00		1,210,944.80	3,249,857.40	1,779,250.80	6,240,053.00	4,559,831.63		
PS		4,151,341.20		4,151,341.20		1,210,794.80	1,574,267.40	581,808.80	3,366,871.00		1,210,794.80	1,574,267.40	581,808.80	3,366,871.00	784,470.20		
MOOE		6,396,816.45		6,396,816.45		150.00	1,675,590.00	1,197,442.00	2,873,182.00		150.00	1,675,590.00	1,197,442.00	2,873,182.00	3,523,634.45		
CO		351,726.98		351,726.98											351,726.98		
UPM Exposure of Reproductive Aged Pregnant and Non-Pregnant Women to Common Environmental Pollutants: Implications to their Reproductive Health, Pregnancy, and Fetal Outcomes (107-151)		6,131,845.60		6,131,845.60		75.00	205,034.01	882,023.80	1,087,132.81		75.00	205,034.01	882,023.80	1,087,132.81	5,044,712.79		
PS		1,564,723.20		1,564,723.20			205,034.01	882,023.80	1,087,057.81			205,034.01	882,023.80	1,087,057.81	477,665.39		
MOOE		2,417,122.40		2,417,122.40		75.00			75.00		75.00			75.00	2,417,047.40		
CO		2,150,000.00		2,150,000.00											2,150,000.00		
UPM Factors Associated with COVID-19 Infection Among Healthcare Workers (107-179)		3,151,286.00		3,151,286.00											3,151,286.00		
PS		1,526,760.00		1,526,760.00											1,526,760.00		
MOOE		1,339,526.00		1,339,526.00											1,339,526.00		
CO		285,000.00		285,000.00											285,000.00		
UPM Formulation and Standardization of Procaine Hydrochloride - Methylprednisolone Sodium Succinate Powder for Injection (107-150)		4,664,424.20	526,521.95	5,190,946.15			198,946.95	264,875.20	463,822.15			198,946.95	264,875.20	463,822.15	4,727,124.90		
PS		1,237,598.40		1,237,598.40			198,871.95	264,875.20	463,747.15			198,871.95	264,875.20	463,747.15	773,851.25		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications, Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (16-19) = (17-18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3)+(4)	6	7	8	9	10=(6)+(7)+(8)+(9)	11	12	13	14	15=(11)+(12)+(13)+(14)	16=(5-10)	17	18
MOOE		1,191,825.80	526,521.95	1,718,347.75			75.00		75.00			75.00		75.00	1,718,272.75		
CO		2,235,000.00		2,235,000.00											2,235,000.00		
UPM Genetics, Immunological and Neurological Long-term Consequences in Prospective COVID-19 Cohort in Thailand, Japan, Philippines, and USA (107-155)		2,919,846.07		2,919,846.07			75.00	438,181.60	438,256.60			75.00	438,181.60	438,256.60	2,481,589.47		
PS		718,363.20		718,363.20				438,181.60	438,181.60				438,181.60	438,181.60	280,181.60		
MOOE		2,051,482.87		2,051,482.87			75.00		75.00			75.00		75.00	2,051,407.87		
CO		150,000.00		150,000.00											150,000.00		
UPM Immune Cell Phenotype Characterization of Moderate to Severe Coronavirus Disease 2019 (COVID-19) Patients at the Philippine General Hospital (107-125) ARCHEER program, PCHRD GIA fund)		738,689.88		738,689.88			614,878.40		614,878.40			614,878.40		614,878.40	123,811.48		
PS		717,265.20		717,265.20			614,728.40		614,728.40			614,728.40		614,728.40	102,536.80		
MOOE		21,424.68		21,424.68			150.00		150.00			150.00		150.00	21,274.68		
UPM Intra-island Zoonotic Transmission of Schistosomiasis in Leyte, the Philippines (107-137)		1,852,122.02		1,852,122.02	150.00			117,600.00	117,750.00	150.00			117,600.00	117,750.00	1,734,372.02		
PS		577,387.20		577,387.20				117,600.00	117,600.00				117,600.00	117,600.00	459,787.20		
MOOE		1,274,734.82		1,274,734.82	150.00				150.00	150.00				150.00	1,274,584.82		
UPM Isolation and Characterization of Antimicrobial-Producing Microorganisms From Mangrove Soils of Alabat Island, Quezon (107-154)		9,098,346.00		9,098,346.00		150.00	185,181.60	578,070.80	763,402.40		150.00	185,181.60	578,070.80	763,402.40	9,098,346.00		
PS		1,093,454.40		1,093,454.40			185,181.60	270,424.40	455,606.00			185,181.60	270,424.40	455,606.00	637,848.40		
MOOE		3,318,294.00		3,318,294.00		150.00		307,646.40	307,796.40		150.00		307,646.40	307,796.40	3,010,497.60		
CO		5,450,000.00		5,450,000.00											5,450,000.00		
UPM Operations Research and Modeling on the Development of a Strategic Roadmap for the Implementation of mHealth Services in the Philippines (107-152)		2,769,395.87		2,769,395.87											2,769,395.87		
PS		2,071,857.60		2,071,857.60											2,071,857.60		
MOOE		697,538.27		697,538.27											697,538.27		
DOST		841,641,104.23	13,527,932.25	855,169,036.48	314,173.48	17,558,218.42	33,428,703.90	51,131,048.33	102,432,144.13	314,173.48	17,558,218.42	33,428,703.90	51,131,048.33	102,432,144.13	752,736,892.35		
		739,183,059.29	1,585,397.29	740,768,456.58	314,173.48	17,558,218.42	32,037,856.89	46,170,344.70	96,080,293.49	314,173.48	17,558,218.42	32,037,856.89	46,170,344.70	96,080,293.49	645,688,163.09		
UPM Operations Research on the Implementation of the Single Joint Ethics Review Process (107-87)		428,387.65		428,387.65		428,387.65			428,387.65			428,387.65		428,387.65			
MOOE		428,387.65		428,387.65		428,387.65			428,387.65			428,387.65		428,387.65			
UPM Perceptions About Ethics of Public Health Interventions During the COVID-19 Outbreak (107-144)		1,361,279.06	1,017,671.94	2,378,951.00		726,718.40	245,374.95	881,785.82	1,853,879.17		726,718.40	245,374.95	881,785.82	1,853,879.17	525,071.83		
PS		851,114.80	858,314.60	1,709,429.40		681,568.40	209,194.40	617,339.80	1,508,102.60		681,568.40	209,194.40	617,339.80	1,508,102.60	281,326.80		
MOOE		510,164.26	159,357.34	669,521.60		45,150.00	36,180.55	264,446.02	345,776.57		45,150.00	36,180.55	264,446.02	345,776.57	323,745.03		
UPM Performance of a Dengue Anti-N S1 Assay for the Determination of Dengue Serostatus Among Children in the Philippines (107-107)		5,000,000.00		5,000,000.00											5,000,000.00		
CO		5,000,000.00		5,000,000.00											5,000,000.00		
UPM Praxis of Participatory Action Research (PAR) for the Department of Health, Philippines: PAR Training and PAR Demonstration Projects (107-168)		3,500,000.00		3,500,000.00											3,500,000.00		
PS		2,815,701.08		2,815,701.08											2,815,701.08		
CO		684,298.92		684,298.92											684,298.92		
UPM Project 1: Biomarkers of Immune Dysfunction in HIV-Associated Metabolic and Neurocognitive Complications (107-138)		52,404,574.00		52,404,574.00	150.00	732,230.00	1,138,540.00	678,207.80	2,549,127.80	150.00	732,230.00	1,138,540.00	678,207.80	2,549,127.80	49,855,446.20		
PS		3,157,320.00		3,157,320.00		732,230.00	1,061,540.00	654,982.80	2,448,752.80		732,230.00	1,061,540.00	654,982.80	2,448,752.80	780,567.20		
MOOE		1,552,254.00		1,552,254.00	150.00		77,000.00	23,225.80	100,375.00	150.00		77,000.00	23,225.00	100,375.00	1,451,879.00		
CO		47,695,000.00		47,695,000.00											47,695,000.00		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications, Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (18-19) = (17-18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3)+(4)	6	7	8	9	10=(6)+(7)+(8)+(9)	11	12	13	14	15=(11)+(12)+(13)+(14)	16=(5-10)	17	18
LPM Project 1. i-FIX: Design and Fabrication of External Fixator (107-132)		10,242,440.48		10,242,440.48	150.00	214,119.20	665,644.80	738,371.20	1,618,285.20	150.00	214,119.20	665,644.80	738,371.20	1,618,285.20	8,624,155.28		
PS		2,257,513.60		2,257,513.60		214,119.20	665,644.80	738,371.20	1,618,135.20		214,119.20	665,644.80	738,371.20	1,618,135.20	639,378.40		
MOOE		3,494,926.88		3,494,926.88	150.00				150.00	150.00				150.00	3,494,776.88		
CO		4,490,000.00		4,490,000.00											4,490,000.00		
LPM Project 1: Cessation of Tobacco (Rugby) Addiction to Adolescents: Using a Rodent Model to Test Novel Pharmacological and Behavioral Treatments for Overcoming Withdrawal and Craving (107-130)		38,467,082.29		38,467,082.29		764,374.80	671,103.60	898,866.55	2,334,344.95		764,374.80	671,103.60	898,866.55	2,334,344.95	36,132,737.34		
PS		2,683,814.40		2,683,814.40		764,224.80	670,953.60	689,141.40	2,124,319.80		764,224.80	670,953.60	689,141.40	2,124,319.80	959,494.60		
MOOE		16,667,053.49		16,667,053.49	150.00		150.00	209,725.15	210,025.15		150.00	150.00	209,725.15	210,025.15	16,657,028.34		
CO		19,116,214.40		19,116,214.40											19,116,214.40		
LPM Project 1: Developing Immersive Technology System (ImTS) for the Management of Patients with Dementia and Behavioral and Psychological Symptoms (107-145)		7,608,643.05		7,608,643.05		855,188.05	365,643.00	1,305,293.36	2,526,124.41			955,188.05	365,643.00	1,305,293.36	2,526,124.41	5,082,518.64	
PS		3,938,748.00		3,938,748.00		770,893.00	365,643.00	1,305,293.36	2,441,829.36		770,893.00	365,643.00	1,305,293.36	2,441,829.36	1,496,918.64		
MOOE		1,590,895.05		1,590,895.05			84,295.05		84,295.05			84,295.05		84,295.05	1,506,600.00		
CO		2,079,000.00		2,079,000.00											2,079,000.00		
LPM Project 1: Next Generation Sequencing-based ex vivo profiling of Breast Cancer using Filpilot and Prediction of Response to Neoadjuvant Therapy in Locoregionally-advanced Breast Cancer in Filpilot (107-139)		21,787,750.80		21,787,750.80		53,858.40	174,917.60	743,969.60	972,745.60			53,858.40	174,917.60	743,969.60	972,745.60	20,815,005.20	
PS		2,642,457.60		2,642,457.60		53,558.40	171,137.60	462,709.60	687,405.60			53,558.40	171,137.60	462,709.60	687,405.60	1,955,052.00	
MOOE		17,705,293.20		17,705,293.20		300.00	3,780.00	281,260.00	285,340.00			300.00	3,780.00	281,260.00	285,340.00	17,419,983.20	
CO		1,440,000.00		1,440,000.00											1,440,000.00		
LPM Project 2. OR PETALS: Operating Room Programmable Electronically Targeted Active Lighting System (107-133)		10,968,614.32		10,968,614.32	150.00	321,254.80	500,277.60	572,407.20	1,394,089.60	150.00	321,254.80	500,277.60	572,407.20	1,394,089.60	9,574,524.72		
PS		2,560,438.40		2,560,438.40		321,254.80	500,277.60	572,407.20	1,393,939.60		321,254.80	500,277.60	572,407.20	1,393,939.60	1,155,498.80		
MOOE		3,247,875.92		3,247,875.92	150.00				150.00	150.00				150.00	3,247,725.92		
CO		5,171,300.00		5,171,300.00											5,171,300.00		
LPM Project 3: Development of a Safe Lactic Acid Bacteria (Lab)-Based Biofunctional Health-Promoting Food as an Adjunct Intervention for the Management of HIV-Associated Metabolic Complications (107-136)		13,237,226.68		13,237,226.68	150.00	603,988.31	692,362.80	955,442.20	2,251,943.31	150.00	603,988.31	692,362.80	955,442.20	2,251,943.31	10,985,283.37		
PS		2,306,044.80		2,306,044.80		603,988.31	692,362.80	799,508.80	2,095,859.91		603,988.31	692,362.80	799,508.80	2,095,859.91	210,184.89		
MOOE		1,576,181.88		1,576,181.88	150.00			135,933.40	136,083.40	150.00			135,933.40	136,083.40	1,440,098.48		
CO		9,355,000.00		9,355,000.00				20,000.00	20,000.00				20,000.00	20,000.00	9,335,000.00		
LPM Project 3. i-Blood: A Compact Device for Measuring Intraoperative Blood Loss in Used Surgical Gauze and Laparotomy packs (107-134)		5,317,768.78		5,317,768.78	150.00	173,129.60	514,353.60	523,105.80	1,210,739.00	150.00	173,129.60	514,353.60	523,105.80	1,210,739.00	4,107,029.78		
PS		1,971,955.20		1,971,955.20		173,129.60	514,353.60	481,588.80	1,169,072.00		173,129.60	514,353.60	481,588.80	1,169,072.00	801,883.20		
MOOE		1,697,813.58		1,697,813.58	150.00			41,517.00	41,667.00	150.00			41,517.00	41,667.00	1,656,146.58		
CO		1,648,000.00		1,648,000.00											1,648,000.00		
LPM Project 4: Surgical Innovation and Biotechnology Laboratory (SIBOL): Establishment of the University of the Philippines College of Medicine (UPCM) - FGH SIBOL (107-135)		6,056,723.51		6,056,723.51	150.00		931,219.60	873,072.80	1,804,442.40	150.00		931,219.60	873,072.80	1,804,442.40	4,252,281.11		
PS		2,581,281.60		2,581,281.60			931,219.60	873,072.80	1,804,292.40			931,219.60	873,072.80	1,804,292.40	776,989.20		
MOOE		3,475,441.91		3,475,441.91	150.00				150.00	150.00				150.00	3,475,291.91		
LPM Prospective Urban and Rural Epidemiologic (PURE) Study (107-172)		7,049,394.61		7,049,394.61											7,049,394.61		
PS		3,873,288.00		3,873,288.00											3,873,288.00		
MOOE		3,176,106.61		3,176,106.61											3,176,106.61		
LPM Rapid Review of COVID-19 Mobile Health Technologies in the Workplace (107-174)		637,675.32		637,675.32											637,675.32		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (18-19) * (17-16)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=3+(-4)	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
PS		637,675.31		637,675.32											637,675.32		
UPM Rapid Review of the Evidence on Prioritized COVID19 Technologies and Interventions (107-143)		1,558,524.16		1,558,524.16				913,436.80	913,436.80				913,436.80	913,436.80	645,087.36		
PS		821,155.20		821,155.20				777,436.80	777,436.80				777,436.80	777,436.80	43,718.40		
MOOE		737,368.96		737,368.96				136,000.00	136,000.00					136,000.00	601,368.96		
UPM Risk Factors, Clinical Characteristics and Transmission Of Covid-19 in Non-Pregnant And Pregnant Women in the Philippines: A MULTICENTER STUDY (107-157)		4,998,251.74	97,527.21	5,095,778.95			575,786.00	1,557,030.91	2,132,816.91			575,786.00	1,557,030.91	2,132,816.91	2,962,962.04		
PS		690,763.20	97,527.21	788,290.41			575,636.00	212,654.41	788,290.41			575,636.00	212,654.41	788,290.41			
MOOE		2,839,888.54		2,839,888.54			150.00		150.00			150.00		150.00	2,839,738.54		
CO		1,467,600.00		1,467,600.00				1,344,376.50	1,344,376.50				1,344,376.50	1,344,376.50	123,223.50		
UPM SARS-Cov-2 Wild Type and Emerging Variants Culture, Isolation, Characterization and Immuno-Challenge Study (107-169)		27,056,247.20		27,056,247.20											27,056,247.20		
PS		2,478,835.20		2,478,835.20											2,478,835.20		
MOOE		10,527,412.00		10,527,412.00											10,527,412.00		
CO		14,050,000.00		14,050,000.00											14,050,000.00		
UPM Seroprevalence of Human Adenovirus 5 Neutralizing Antibodies in an Adult Population from Urban Philippines: Implications on Adenoviral Vector-Based SARS-CoV-2 Vaccines (107-143)		4,999,972.01		4,999,972.01		197,114.92	394,024.40	723,602.00	1,414,741.32		197,114.92	394,024.40	723,602.00	1,414,741.32	3,585,230.69		
PS		778,857.60		778,857.60		128,419.20	325,914.40	162,262.00	616,595.60		128,419.20	325,914.40	162,262.00	616,595.60	162,262.00		
MOOE		1,945,664.41		1,945,664.41		168,695.72	44,110.00	561,340.00	774,145.72		168,695.72	44,110.00	561,340.00	774,145.72	1,171,518.69		
CO		2,275,450.00		2,275,450.00			24,000.00		24,000.00			24,000.00		24,000.00	2,251,450.00		
UPM SIBOL Fabrication and Characterization of UV and Hydrogen Peroxide Vaporization for Decontamination of N95 Respirators (107-149)		3,359,689.20	128,116.19	3,487,805.39		159,480.73	421,019.46	132,942.00	813,442.19		159,480.73	421,019.46	132,942.00	813,442.19	2,674,363.20		
PS		685,176.00	128,116.19	813,292.19		159,330.73	421,019.46	132,942.00	813,292.19		159,330.73	421,019.46	132,942.00	813,292.19			
MOOE		884,513.20		884,513.20		150.00			150.00		150.00			150.00	884,363.20		
CO		1,790,000.00		1,790,000.00											1,790,000.00		
UPM Solidarity Vaccine Trial in the Philippines: Randomized Trial of Candidate Vaccines of COVID- 9 (107-118)		429,322,490.00		429,322,490.00	313,123.48	7,663,711.62	16,619,965.62	25,047,182.96	49,643,983.68	313,123.48	7,663,711.62	16,619,965.62	25,047,182.96	49,643,983.68	379,678,506.32		
PS		196,316,358.00		196,316,358.00	313,123.48	7,167,431.62	15,668,225.62	23,221,061.00	46,369,841.72	313,123.48	7,167,431.62	15,668,225.62	23,221,061.00	46,369,841.72	149,946,516.28		
MOOE		216,214,787.00		216,214,787.00		1,280.00	148,000.00	1,139,521.96	1,288,801.96		1,280.00	148,000.00	1,139,521.96	1,288,801.96	214,925,985.04		
CO		16,791,345.00		16,791,345.00		495,000.00	803,740.00	686,600.00	1,985,340.00		495,000.00	803,740.00	686,600.00	1,985,340.00	14,806,085.00		
UPM Support for the 23rd National Institutes of Health Anniversary (107-148)		99,000.00		99,000.00		90,150.00	6,000.00	2,850.00	99,000.00		90,150.00	6,000.00	2,850.00	99,000.00			
MOOE		99,000.00		99,000.00		90,150.00	6,000.00	2,850.00	99,000.00		90,150.00	6,000.00	2,850.00	99,000.00			
UPM Understanding the Psychosocial Impact of the COVID-19 Experience on Patients and Their Families in Metro Manila, Philippines (107-171)		1,299,884.96		1,299,884.96											1,299,884.96		
PS		1,180,670.40		1,180,670.40											1,180,670.40		
MOOE		59,214.56		59,214.56											59,214.56		
CO		60,000.00		60,000.00											60,000.00		
UPM Vaccine Immune Response and Outcome Monitoring with Epitope Sequences (VIROMES): Application to Philippine WHO SOLIDARITY COVID-19 Vaccine Trial (107-173)		3,590,176.20		3,590,176.20											3,590,176.20		
PS		1,166,287.20		1,166,287.20											1,166,287.20		
MOOE		945,889.00		945,889.00											945,889.00		
CO		1,478,000.00		1,478,000.00											1,478,000.00		
UPM Special Risk Allowance of COVID Laboratory Staff (103-288)		485,000.00		485,000.00			477,727.25		477,727.25			477,727.25		477,727.25	7,272.75		
PS		485,000.00		485,000.00			477,727.25		477,727.25			477,727.25		477,727.25	7,272.75		

Source Agencies and Projects	LACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications, Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (10-19) = (17-18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3)+(4)	6	7	8	9	10=(6)+(7)+(8)+(9)	11	12	13	14	15=(11)+(12)+(13)+(14)	16=(5-10)	17	18
LPM Double-Blind, Placebo-Controlled, Randomized Controlled Trial to Assess the Efficacy, Safety, and Effect on Viral Clearance of Ivermectin in Asymptomatic and Non-Severe COVID-19 Patients Confined in Isolation Facilities (107-160)		32,987,604.89	10,942,534.96	43,930,139.85				308,643.60	308,643.60				308,643.60	308,643.60	43,621,496.25		
PS		3,513,752.00		3,513,752.00				308,343.60	308,343.60				308,343.60	308,343.60	3,205,408.40		
MOOE		29,313,852.89	10,942,534.96	40,256,387.85				300.00	300.00				300.00	300.00	40,256,087.85		
CO		160,000.00		160,000.00											160,000.00		
DOST		192,459,044.94	10,942,534.96	113,400,579.90			1,390,847.01	4,961,003.63	6,351,850.64			1,390,847.01	4,961,003.63	6,351,850.64	107,048,728.26		
LPM Immune Response of COVID-19 Peptide-loaded Allogeneic Dendritic Cells (107-158)		1,790,475.25		1,790,475.25			311,689.20	320,208.85	631,898.05			311,689.20	320,208.85	631,898.05	1,158,577.20		
PS		632,608.80		632,608.80			311,539.20	258,269.60	569,808.80			311,539.20	258,269.60	569,808.80	62,800.00		
MOOE		1,157,866.45		1,157,866.45			150.00	61,939.25	62,089.25			150.00	61,939.25	62,089.25	1,095,777.20		
CO																	
LPM Philippine Vaccine Effectiveness Project: A Post COVID-19 Vaccination Surveillance Among Fully-vaccinated Adults (107-161)		35,572,260.14		35,572,260.14			1,878,514.40	1,878,664.40				150.00	1,878,514.40	1,878,664.40	33,693,595.74		
PS		11,623,508.80		11,623,508.80				1,878,514.40	1,878,514.40				1,878,514.40	1,878,514.40	9,743,994.40		
MOOE		21,790,751.34		21,790,751.34			150.00		150.00			150.00		150.00	21,790,601.34		
CO		2,159,000.00		2,159,000.00											2,159,000.00		
LPM Project 1: Isolation of African Swine Fever Virus and Other Swine Related Viruses in the Philippines (107-164)		6,232,741.56		6,232,741.56				281,973.95	281,973.95				281,973.95	281,973.95	5,940,767.61		
PS		683,731.20		683,731.20				281,823.95	281,823.95				281,823.95	281,823.95	401,907.25		
MOOE		3,339,010.36		3,339,010.36				150.00	150.00				150.00	150.00	3,338,860.36		
CO		2,200,000.00		2,200,000.00											2,200,000.00		
LPM Project 1: Science-based Clinical Research Hub Management Practices (107-162)		2,464,013.32		2,464,013.32				554,956.80	554,956.80				554,956.80	554,956.80	1,909,056.52		
PS		1,305,035.20		1,305,035.20				554,806.80	554,806.80				554,806.80	554,806.80	750,228.40		
MOOE		673,559.99		673,559.99				150.00	150.00				150.00	150.00	673,409.99		
CO		485,418.13		485,418.13											485,418.13		
LPM Project 2: Portable Sequencing Platform for African Swine Fever Virus Detection (107-165)		2,706,988.66		2,706,988.66				150.00	150.00				150.00	150.00	2,706,838.66		
MOOE		256,988.66		256,988.66				150.00	150.00				150.00	150.00	256,838.66		
CO		2,450,000.00		2,450,000.00											2,450,000.00		
LPM Project 2: Portable Sequencing Platform for African Swine Fever Virus Detection (107-165)		960,267.20		960,267.20				729,229.89	729,229.89				729,229.89	729,229.89	231,037.31		
PS		960,267.20		960,267.20				729,229.89	729,229.89				729,229.89	729,229.89	231,037.31		
LPM Salaries of COVID Laboratory Staff, July & August 2021 (103-18E)		1,999,143.60		1,999,143.60			601,130.56		601,130.56			601,130.56		601,130.56	1,398,013.04		
PS		1,999,143.60		1,999,143.60			601,130.56		601,130.56			601,130.56		601,130.56	1,398,013.04		
LPM Solidarity Treatment Trial Plus: An International Randomized Trial of Additional Treatments for Covid-19 in Hospitalized Patients who are all Receiving the Local Standard of Care (107-159)		17,120,890.32		17,120,890.32			150.00	743,636.00	743,786.00			150.00	743,636.00	743,786.00	16,377,104.32		
PS		3,038,009.60		3,038,009.60				743,636.00	743,636.00				743,636.00	743,636.00	2,294,373.60		
MOOE		14,082,880.72		14,082,880.72			150.00		150.00			150.00		150.00	14,082,730.72		
LPM Support for publication of the research paper entitled: "Health Information Systems for Older Persons in Select Government Tertiary Hospitals and Health Centers in the Philippines: Cross-Sectoral Study" in the Journal of Medical Internet Research		148,660.00		148,660.00				143,690.14	143,690.14				143,690.14	143,690.14	4,969.86		
MOOE		148,660.00		148,660.00				143,690.14	143,690.14				143,690.14	143,690.14	4,969.86		
National Commission for Culture and the Arts (NCCA)		360,000.00		360,000.00			16,000.00		16,000.00			16,000.00		16,000.00	344,000.00		
		360,000.00		360,000.00			16,000.00		16,000.00			16,000.00		16,000.00	344,000.00		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (10-19) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+(-4))	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
UPM Establishment of a Pocket Museum and Online Resource on the History of Rizal Hall and other Historical Buildings in the UPM (105)		360,000.00		360,000.00			16,000.00		16,000.00			16,000.00		16,000.00	344,000.00		
PS		252,000.00		252,000.00			16,000.00		16,000.00			16,000.00		16,000.00	236,000.00		
MOOE		108,000.00		108,000.00											108,000.00		
Philhealth		203,551.56		203,551.56											203,551.56		
		203,551.56		203,551.56											203,551.56		
UPM Validating the Performance of the National Health Insurance Program (153C)		203,551.56		203,551.56											203,551.56		
MOOE		203,551.56		203,551.56											203,551.56		
PITAHC		399,823.98		399,823.98		137,375.70			137,375.70		137,375.70			137,375.70	262,448.28		
		399,823.98		399,823.98		137,375.70			137,375.70		137,375.70			137,375.70	262,448.28		
UPM Formulation and in vivo Evaluation Studies of Syrup and Tablet Containing Alternanthera versicolor and Phyllanthus niruri aqueous Crude Extracts for Anemia and Thrombocytopenia (Phase I) 165-16		399,823.98		399,823.98		137,375.70			137,375.70		137,375.70			137,375.70	262,448.28		
PS		267,004.00		267,004.00		30,278.40			30,278.40		30,278.40			30,278.40	236,725.60		
MOOE		132,819.98		132,819.98		107,097.30			107,097.30		107,097.30			107,097.30	25,722.68		
GRAND TOTAL		893,658,791.78	16,273,970.22	909,932,642.00	314,173.48	27,382,141.69	47,670,486.80	51,427,726.33	126,714,528.30	314,173.48	27,382,141.69	47,670,486.80	51,427,726.33	126,714,528.30	783,218,113.79		
PS		312,423,051.34	3,818,228.33	316,241,279.67	313,123.48	20,345,185.95	39,498,632.77	43,393,179.59	103,550,121.79	313,123.48	20,345,185.95	39,498,632.77	43,393,179.59	103,550,121.79	212,691,157.88		
MOOE		423,121,163.01	12,455,691.89	435,576,844.90	1,050.00	6,461,955.74	7,344,114.03	5,983,578.24	19,790,690.01	1,050.00	6,461,955.74	7,344,114.03	5,983,578.24	19,790,690.01	415,786,154.89		
CO		158,114,517.43		158,114,517.43		495,000.00	827,740.00	2,050,976.50	3,373,716.50		495,000.00	827,740.00	2,050,976.50	3,373,716.50	154,740,800.93		

Certified Correct:

Certified Correct:

Recommended By:

Approved By:


LOVELLE C. SAGUID
Chief Budget Officer


ERWIN A. DANDO, CPA
Chief Accountant


MICHAEL L. TEE, MD, MHPEd
Vice Chancellor for Planning and Development


CARMENCITA D. PADILLA, MD, MAHPs
Chancellor

Date:

Date:

Date:

Date: